What Vascor Treats

Vascor, known by the generic name bepridil, is a calcium channel blocker that was primarily utilized for the management of chronic stable angina pectoris. Angina is characterized by chest pain or discomfort that occurs when the heart muscle does not receive an adequate supply of oxygen-rich blood, often due to the narrowing of the coronary arteries.

Main Uses

The medication was specifically indicated for patients who had not responded adequately to other anti-anginal therapies. Its primary applications included:

• Chronic Stable Angina: Management of predictable chest pain associated with physical exertion or emotional stress.
• Vasodilation: Promoting the relaxation of blood vessels to improve blood flow and reduce the workload on the heart.

Benefits and Mechanism of Action

Vascor functions by inhibiting the movement of calcium ions into the smooth muscle cells of the coronary and peripheral arterial beds, as well as the specialized conducting tissue of the heart. This action provides several clinical benefits:

• Reduction in Anginal Frequency: By improving the balance between myocardial oxygen supply and demand, the medication helps reduce the frequency of chest pain episodes.
• Increased Exercise Tolerance: Patients may experience an improved ability to engage in physical activity without the onset of anginal symptoms.
• Heart Rate Modulation: It can help slow the heart rate and reduce the force of contraction, further lowering the heart's oxygen requirements.
• Dual Channel Blockade: Unlike some other calcium channel blockers, bepridil affects both the slow calcium channels and fast sodium channels, providing a distinct pharmacological profile in the management of cardiovascular symptoms.

Who Can and Cannot Use Vascor?

The official regulatory profile for Vascor (bepridil) defines specific patient populations who are eligible for use, who require caution, and who are strictly prohibited from using the medicine (contraindicated).

Contraindicated Populations (Must Not Use)

Vascor is formally contraindicated and must not be used by patients with several conditions, including known hypersensitivity to bepridil, uncompensated cardiac insufficiency or severe left ventricular dysfunction, and specific cardiac conduction abnormalities such as congenital QT interval prolongation, sick sinus syndrome, or high-degree AV block (unless a pacemaker is present). Use is also prohibited in patients with clinically significant hypotension (systolic blood pressure below 90 mm Hg) and those with uncorrected hypokalemia or hypomagnesemia. Furthermore, Vascor is contraindicated for those taking other drugs that prolong the QT interval.

Restricted and Conditional Use

Use is reserved for adults with chronic stable angina whose condition has shown an incomplete response to, or who are intolerant of, other standard anti-anginal treatments. Safety and efficacy have not been established in pediatric patients (under age 18). Use requires caution in patients with impaired hepatic or renal function due to limited safety data. The medicine is not recommended during pregnancy or lactation unless the documented benefit is judged to outweigh the potential risk.

The interaction profile of Vascor (Simvastatin) is defined by its metabolic clearance and its potential for additive muscle toxicity, as detailed in regulatory documents.

Contraindicated Combinations

A large number of medicinal products are documented as contraindicated combinations. This prohibition is based on the pharmacokinetic finding that Simvastatin is a substrate of the enzyme CYP3A4 and the transporter OATP1B1, where strong inhibition drastically increases systemic exposure. Prohibited agents include certain strong CYP3A4 inhibitors (e.g., Clarithromycin, select azole antifungals, HIV protease inhibitors), as well as Ciclosporin, Danazol, and Gemfibrozil.

Exposure Modification and Restrictions

Other agents have maximum daily dose restrictions mandated by regulatory authorities. For example, the Simvastatin dose must not exceed 10 mg daily when co-administered with Verapamil or Diltiazem, and should not exceed 20 mg daily with agents such as Amiodarone or Amlodipine.

Pharmacodynamic interactions are documented with Coumarin Anticoagulants, which may potentiate the International Normalized Ratio (INR), and with Colchicine, due to an additive risk of muscle toxicity.

Consumption of large quantities of grapefruit juice is restricted as it significantly raises Simvastatin plasma levels. A timing rule requires administering Simvastatin at least two hours before or four hours after bile acid sequestrants to maintain proper absorption. Furthermore, certain Chinese patients may have a higher documented risk of myopathy when co-administered with lipid-modifying doses of Niacin.

How Vascor Works: Mechanism of Action

Inhibiting Internal Cholesterol Synthesis

Vascor's mechanism initiates at the molecular level where its active form acts as a competitive inhibitor of the enzyme HMG-CoA reductase. This enzyme controls the rate-limiting step in the mevalonate pathway in the liver, reducing the cell's endogenous production of cholesterol. This molecular blockade initiates a compensatory feedback loop that contributes to the drug's systemic physiological action.

Enhancing LDL Clearance from the Bloodstream

The acute depletion of internal cholesterol activates a cellular response that significantly up-regulates the number of Low-Density Lipoprotein (LDL) receptors on the liver cell surface. This increase in receptor density enhances the liver's capacity to extract and remove circulating LDL-C particles from the plasma, resulting in a reduction of the systemic atherogenic lipoprotein concentration.

Modulating Vascular Cell Signaling

Beyond its lipid-lowering cascade, the drug also modulates the synthesis of non-sterol intermediates (isoprenoids) within the mevalonate pathway. This inhibition affects the prenylation of key signaling proteins (GTPases) which, in turn, enhances endothelial nitric oxide synthase (eNOS) activity, which modulates vascular endothelial activity and influences vessel wall signaling.

Instruction Map: How to use Vascor — Official Administration Guidelines

Instruction Classifications (High-Level)

Resulting Procedural Structure

Official step sequence:

• Initiate therapy with the standard starting dose of 200 mg once daily.
• Maintain the dose for a minimum of 10 days before considering adjustment.
• Adjust the dose, if deemed necessary, in 100 mg increments, up to the maximum 400 mg.

Connection to the overall use protocol: The official use protocol for Vascor is structured as a long-term, oral, once-daily regimen with high specificity around dosage adjustment. Instructions mandate a minimum 10-day interval between any dose increase, reflecting the time needed for the medicine to achieve steady-state blood levels. The labeled instructions also note that the initial dose may require modification for patients with hepatic impairment.

Research Evidence / Overview of Studies for Vascor (Bepridil)

Evidence from Studies on Chronic Stable Angina

The core research has focused on exploring the use of Vascor in conditions characterized by fluctuating or episodic manifestations, specifically chronic stable angina pectoris. The main body of evidence was evaluated in rigorous research designs, including randomized controlled trials (RCTs) and double-blind crossover trials. These studies research examined how the medicine was observed in adult patients over relatively short time intervals, typically ranging from a few weeks to a few months.

The clinical trials research examined outcomes related to physical discomfort, specifically monitoring how frequently patients experienced angina and how often they required symptom relief medication, such as nitroglycerin. Another critical area of focus studies explored was outcomes reflecting daily functioning or activity level, assessed by measuring the duration of exercise performed by patients—often on a treadmill—before symptoms began.

Findings describe patterns observed in the studies where participants receiving the medication reported measurements of anginal attacks and consumption of rescue medication that varied compared to those receiving placebo. Research describes observations measured during the study period related to changes in patients' exercise capacity. Because the primary efficacy studies were designed to assess these short-term symptom changes and functional measures, they do not provide extensive data on long-term cardiac events.

Research Focus on Difficult-to-Treat Angina

Vascor was studied for use in a specific group of patients: those who either experienced an incomplete result from, or could not tolerate, other commonly used anti-anginal treatments. The research focus centers on this particular research scenario, meaning the main evidence was evaluated in patient populations where symptoms of angina was observed in a condition involving periods of heightened symptoms.

Long-Term Research and Follow-up Duration

Clinical trials for Vascor include both short-term comparison phases and certain extended-duration follow-up protocols. The initial, most rigorous comparisons against placebo follow-up durations were limited, typically lasting only a few weeks. Beyond these initial periods, some studies were observed in patients who continued treatment for extended time intervals, sometimes nine months or longer, in specialized withdrawal studies. These long-term observations studies report how symptoms were monitored in the observed populations, and explored whether the patterns observed in the short-term trials were sustained. However, long-term effects are not fully established because the evidence generally focuses on symptom patterns during extended use rather than tracking hard cardiovascular outcomes, such as long-term survival or preventing heart attacks, over many years.

Key Studies & References

1. Sustained antianginal efficacy of bepridil in patients with chronic stable angina: a placebo-controlled withdrawal study
2. World Health Organization Model List of Essential Medicines (Relevant to assessing drug class and global context of evidence)

Common questions about Vascor (FAQ)

Q: Does this medication cause weight gain?

Weight gain has been listed as a potential side effect in clinical trials documented for this medication. As with any side effect, it may not affect everyone who uses Vascor. The official product information includes weight changes among the possible undesirable effects reported.

Q: Is it safe to take this for a long time?

Official product information addresses considerations related to long-term use. Regulatory documents address potential withdrawal reactions that have been associated with sudden discontinuation of the medication. For certain populations, such as children and adolescents, official information may note that there is a lack of long-term data regarding effects on growth and development.

Q: Can children 2 years old use it?

According to the official product labeling, the safety and effectiveness of Vascor have not been established in the pediatric population. Therefore, the medication is not approved for use in young children. In many regions, regulatory agencies specify that this product should not be used in individuals under 18 years of age.

Storage and Handling

Vascor (bepridil hydrochloride) must be stored at Controlled Room Temperature, a range officially defined as 15 C to 30 C (59 F to 86 F). The medication requires specific handling precautions to maintain stability:

• Protection: The tablets must be kept from freezing and stored away from direct sunlight and moisture.
• Container: Keep the container tightly sealed.
• Safety: Always keep Vascor out of the reach and sight of children.

Disposal Instructions

Official regulatory guidance outlines specific procedures for discarding unused or expired Vascor. The preferred method is utilizing a community drug take-back program.

Vascor is not on the list of medicines recommended for flushing; therefore, it must not be disposed of by pouring it down a sink or toilet. If a take-back program is unavailable, follow precautions for household trash disposal, such as mixing the tablets with an undesirable substance and obscuring all personal information on the original container.